News

Video

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

Author(s):

Rana R. McKay, MDTanya B. Dorff, MD

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Related Videos
Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Kara N. Maxwell, MD, PhD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Related Content
Philip Sutera, MD, of Johns Hopkins University School of Medicine
May 30th 2024

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
May 6th 2024

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Marcelo Bigarella, MD
May 4th 2024

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer